NLRP3 and cryopyrin-associated periodic syndrome: In NLRP3-AID, complaints of headache and dizziness were significantly more common (P value=0.0176), consistent with a previous report of 79% of CAPS patients with known pathogenic NLRP3 variants and 73% of those with low-penetrance variants (9).